Qiagen (QGEN) Tops Q1 EPS by 7c; Suspends Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
QIAGEN Reports Full Results for First Quarter of 2020
May 6, 2020 4:05 PM EDTQ1 2020 results: Net sales of $372.1 million (+7% actual, +9% CER vs. ~+2-3% CER outlook) Diluted EPS $0.17; adjusted EPS $0.34 ($0.34 CER vs. ~$0.28-0.29 CER outlook) Fully mobilized teams addressing COVID-19 pandemic testing demand, dramatically ramping up production of RNA extraction kits, QIAstat-Dx tests and components for third-party tests QIAGEN expects higher results for Q2 2020 based on trends to date and suspends outlook for full-year 2020
VENLO, Netherlands--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:... More
